GLP-1s After Two Years: Staying On, Stepping Down, or Coming Off

Most GLP-1 coverage stops at the one-year mark, because that is where most of the trials stop. But the question people actually ask around month twelve is the one with the least written about it: what happens after that? Do you stay on this for the rest of your life, step down to something smaller, or come off it altogether?

There is now enough two-year data, withdrawal data and real-world data to answer it properly. The answer is not the same for everyone, and it is not the one either side of the argument wants.

If you stay on, the loss holds

The longest randomised look at continuous treatment is STEP 5, which ran semaglutide 2.4 mg for 104 weeks. Mean weight change was −15.2% at two years, against −2.6% on placebo.

The more interesting number is the comparison within the treatment group: −15.6% at week 52 and −15.2% at week 104. Essentially flat. The weight came off in the first year and then stayed off, for as long as treatment continued. There is no evidence here of the drug wearing out.

If you stop abruptly, most of it comes back

Two trials tested this directly, and they agree. In the STEP 1 extension, participants regained roughly two-thirds of the weight they had lost in the year after stopping semaglutide.

SURMOUNT-4 is the sharper test. Participants took tirzepatide for 36 weeks, then half were switched to placebo for 52 weeks. Among those switched, 82% regained more than a quarter of the weight they had lost. The cardiometabolic improvements — blood pressure, lipids, glycaemia — reversed along with the weight.

But read the other half of that result, because it almost never gets quoted: the withdrawal group still finished 9.9% below their starting weight, and 46.2% were still at least 10% down a full year after stopping. Stopping is not a reset to zero. It is a partial give-back.

The number nobody plans for: most people stop anyway

Here is where the clinical literature and real life diverge. Guidelines assume continuous treatment. Most people do not manage it.

In a Danish nationwide cohort, 52% of adults stopped semaglutide for weight loss within one year — 18% by three months, 31% by six, 42% by nine. US insurance data shows the same pattern improving but not solved: one-year persistence rose from 33.2% in 2021 to 60.9% by the first half of 2024.

So roughly four in ten people are still off treatment inside a year, for reasons that are rarely clinical: cost, coverage changes, side effects, supply, or simply deciding they are done. Which means the off-ramp is not a hypothetical to plan for someday. For most people it is the thing that is actually going to happen, and the only real question is whether it happens on purpose or by accident.

What the guidelines say — and where they stop

Be clear about this, because it cuts against the popular framing: the January 2026 Standards of Care in Overweight and Obesity, from the Obesity Association, state that obesity pharmacotherapy indicated for chronic therapy should be continued beyond reaching weight-loss goals, precisely because stopping tends to bring back both the weight and the cardiometabolic risk.

The default clinical answer, in other words, is to keep going. Obesity is framed as a chronic condition, and nobody expects a blood-pressure medicine to be stopped once blood pressure normalises.

What the guidelines do not provide is a protocol for the people who are going to stop regardless. There is no FDA-established tapering schedule. Lower-dose maintenance looks promising — some clinicians use the lowest dose that holds the weight rather than the maximum tolerated dose — and small studies suggest a gradual reduction paired with real lifestyle structure holds weight better than an abrupt stop. But this is thin evidence compared with everything else on this page, and it deserves to be labelled as such.

So who can realistically come off?

Nobody can tell you this from a web page, and anyone who says otherwise is selling something. But the evidence does sketch two different profiles.

More likely to hold after stepping down: people who reached a stable weight well before stopping, who built resistance training and a protein-adequate diet during treatment rather than relying on appetite suppression alone, whose metabolic markers normalised, who have time and support for close follow-up, and who taper gradually rather than stopping outright.

More likely to regain: people who stop abruptly, who stop at maximum dose while still actively losing, who never changed the surrounding habits, who have a long history of weight cycling, or who are stopping for a reason that has nothing to do with readiness — a formulary change, a price rise, a supply gap.

What to ask before you decide

1. 1.Is my weight actually stable? Stopping mid-loss is a different proposition from stopping after six months at a plateau.
2. 2.What is the lowest dose that holds this? Stepping down is a third option between staying at full dose and stopping, and it is the one most often skipped.
3. 3.What is my regain plan? Decide in advance what degree of regain would mean restarting, and how quickly you could.
4. 4.What did my markers do? Blood pressure, lipids and A1c improving on treatment are part of what you are weighing — SURMOUNT-4 showed those reverse along with the weight.
5. 5.What am I actually optimising for? Cost, needle fatigue and side effects are all legitimate reasons to change course. They just call for different plans than readiness does.